We recently published a list of Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against Billionaire Glenn Russell Dubin’s other stock picks with huge upside potential.
Glenn Russell Dubin is one of the industry’s most experienced hedge fund managers, best known as the co-founder of Highbridge Capital Management, a multi-strategy investment business he founded with Henry Swieca in 1992. Before being bought by JPMorgan Chase in 2004, the firm quickly rose to prominence as one of Wall Street’s most sophisticated hedge funds. As of March 2024, Highbridge Capital manages more than $7.1 billion in discretionary assets and has a focused exposure to growth industries.
Dubin has long been involved in basic research and multi-asset investing through Highbridge and his private investment firm, Dubin & Company. His portfolio demonstrates a high-conviction strategy, with the top ten holdings accounting for more than 40% of reported 13F equities. Dubin’s top stock picks frequently coincide with broader macroeconomic themes, such as monetary easing, capital market expansion, and industrial revival, making them excellent bets for long-term investors looking for asymmetric risk-reward ratios.
The background for these investments is especially attractive. Financial markets rebounded strongly in 2024, with financial equities up more than 30% by the end of the year, owing to lower inflation, lower interest rates, and strong investor sentiment. Even if the United States’ GDP growth is expected to fall from 2.7% in 2024 to 1.5% in 2025, hopes of Fed rate cuts and a more stable regulatory environment are keeping financial industry momentum alive. Meanwhile, growing corporate refinancing needs and record-high consumer debt are steering capital into private credit and asset-backed lending—areas where Highbridge has traditionally excelled.
The industrial sector is also experiencing a significant revival, with a 26% increase in 2024 driven by demand for reshored manufacturing, clean energy buildout, and infrastructure construction. With only a quarter of the $1.9 trillion in planned North American infrastructure projects underway, there is still enormous growth potential. At the same time, reduced interest rates are expected to boost housing activity, and aerospace demand is expected to rise as airlines revamp their aged fleets. These macroeconomic drivers continue to provide appealing entry points for cyclical names with long-term upside.
Tariff concerns have increased volatility in the equity markets, particularly in light of proposed higher tariffs on steel and aluminum imports. However, other investors see this as a temporary disruption that could eventually benefit domestic manufacturers and capital goods industries. In reality, leading market commentators argue that predictions of a fresh wave of trade protectionism are exaggerated, with underlying fundamentals remaining strong across major value industries.
In that scenario, this may be a good time to follow experienced managers such as Glenn Dubin. As markets reset and valuations in banking and industrial stocks decline from their 2024 highs, the opportunity to purchase into structurally good companies at a discount is wide open. Highbridge Capital’s recent bets indicate trust in sectors that are not only rebounding but evolving, and these top stock picks might provide considerable upside as the market rebalances in 2025.
Methodology
To compile a list of Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential, we studied Greenlight Capital’s Q4 2024 13F filings to identify billionaire Glenn Russell Dubin’s stock picks with the most upside potential. We evaluated the firms in ascending order of upside potential. These stocks are also popular with elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Number of Hedge Fund Holders: 50
Upside Potential: 226.16%
A commercial-stage biotech company, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) focuses on developing genetic medications for uncommon neuromuscular disorders. Its gene and RNA-targeted treatments for Duchenne muscular dystrophy (DMD) include EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS. In addition, the company is developing siRNA-based therapeutics for other uncommon genetic illnesses and treatments for different types of limb-girdle muscular dystrophies (LGMD).
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reported $612 million in total net product revenue for the quarter that ended March 31, 2025, a 70% increase from the previous year. ELEVIDYS drove the majority of growth, generating $375 million in revenue — a 180% increase year-over-year. The PMO franchise increased by 5%, adding $237 million. However, because of difficulties with the supply of ELEVIDYS, the company reduced its full-year revenue projection to $2.3–$2.6 billion. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) would have generated a GAAP operating profit of $283 million and a non-GAAP operating profit of $334 million, excluding the $584 million R&D expense related to the Arrowhead collaboration.
Despite strong demand, short-term momentum was hampered by operational delays and a patient safety incident. While no widespread safety issues were identified among the 800+ treated patients, a single case of sudden liver failure led to the rescheduling of infusions. The Q1 shortfall also stemmed from extended treatment timelines and mismatched site capacities. Approximately 60% of ELEVIDYS’ revenue came from top-tier sites, which were at full capacity, prompting the company to shift patients to alternative locations.
Key programs like SRP-9003 and SRP-9004 for LGMD have reached enrollment milestones and are on track for regulatory submissions later in 2025, reflecting continued pipeline progress. Readouts of Sarepta’s siRNA treatments for FSHD1 and DM1 are anticipated later this year.
One of the largest holdings of billionaire Glenn Russell Dubin’s portfolio is Sarepta Therapeutics, Inc. (NASDAQ:SRPT), which accounted for 2.37% of his portfolio at the end of Q4 2024. The company continues to be one of the best biotech choices with enormous upside potential as it overcomes immediate obstacles and expands access to ELEVIDYS.
Overall, SRPT ranks 1st on our list of Billionaire Glenn Russell Dubin’s stock picks with huge upside potential. While we acknowledge the potential of SRPT, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than SRPT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
